Loss of miR-378 in prostate cancer, a common regulator of KLK2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients

Biological Chemistry

Volumn 395, Issue 9, 2014, Pages 1095-1104

  Avgeris, Margaritis ^a   Stravodimos, Konstantinos ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Kallikrein related peptidase; KLK; miR 378a; miR 422a; Molecular tumor markers; Prostate tumors

Indexed keywords

COMPLEMENTARY DNA; KALLIKREIN RELATED PEPTIDASE 2; KALLIKREIN RELATED PEPTIDASE 4; MICRORNA; MICRORNA 378; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; UNCLASSIFIED DRUG; KALLIKREIN; KALLIKREIN 4; KLK2 PROTEIN, HUMAN; MIRN378 MICRORNA, HUMAN;

CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; ENZYME REGULATION; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; BLOOD; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK FACTOR; TIME; TUMOR INVASION; TUMOR RECURRENCE;

DISEASE-FREE SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 84926431815     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2014-0150     Document Type: Conference Paper

References (37)

1. Andriole, G.L., Crawford, E.D., Grubb, R.L., 3rd, Buys, S.S., Chia, D., Church, T.R., Fouad, M.N., Gelmann, E.P., Kvale, P.A., Reding, D.J., et al. (2009). Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319.
2. Avgeris, M., Mavridis, K., and Scorilas, A. (2010). Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol. Chem. 391, 505-511.
3. Avgeris, M., Stravodimos, K., and Scorilas, A. (2011). Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance. Prostate 71, 1780-1789.
4. Avgeris, M., Mavridis, K., and Scorilas, A. (2012). Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol. Chem. 393, 301-317.
5. Avgeris, M., Stravodimos, K., Fragoulis, E.G., and Scorilas, A. (2013). The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br. J. Cancer 108, 2573-2581.
6. Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.
7. Bartels, C.L. and Tsongalis, G.J. (2009). MicroRNAs: novel biomarkers for human cancer. Clin. Chem. 55, 623-631.
8. Borgono, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280.
9. Calin, G.A. and Croce, C.M. (2006). MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866.
10. Chen, L.T., Xu, S.D., Xu, H., Zhang, J.F., Ning, J.F., and Wang, S.F. (2012). MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med. Oncol. 29, 1673-1680.
11. Chow, T.F., Crow, M., Earle, T., El-Said, H., Diamandis, E.P., and Yousef, G.M. (2008). Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol. Chem. 389, 731-738.
12. Darson, M.F., Pacelli, A., Roche, P., Rittenhouse, H.G., Wolfert, R.L., Young, C.Y., Klee, G.G., Tindall, D.J., and Bostwick, D.G. (1997). Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49, 857-862.
13. Fendler, A., Stephan, C., Yousef, G.M., and Jung, K. (2011). MicroRNAs as regulators of signal transduction in urological tumors. Clin. Chem. 57, 954-968.
14. Feng, M., Li, Z., Aau, M., Wong, C.H., Yang, X., and Yu, Q. (2011). Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene 30, 2242-2251.
15. Freedland, S.J. (2011). Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 117, 1123-1135.
16. Ganesan, J., Ramanujam, D., Sassi, Y., Ahles, A., Jentzsch, C., Werfel, S., Leierseder, S., Loyer, X., Giacca, M., Zentilin, L., et al. (2013). MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127, 2097-2106.
17. Herrala, A.M., Porvari, K.S., Kyllonen, A.P., and Vihko, P.T. (2001). Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer 92, 2975-2984.
18. Klokk, T.I., Kilander, A., Xi, Z., Waehre, H., Risberg, B., Danielsen, H.E., and Saatcioglu, F. (2007). Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res. 67, 5221-5230.
19. Knezevic, I., Patel, A., Sundaresan, N.R., Gupta, M.P., Solaro, R.J., Nagalingam, R.S., and Gupta, M. (2012). A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. J. Biol. Chem. 287, 12913-12926.
20. Larne, O., Edsjo, A., Bjartell, A., and Ceder, Y. (2009). Development of a miRNA assay for prostate cancer detection. Eur. Urol. Suppl. 8, S316.
21. Larne, O., Martens-Uzunova, E., Hagman, Z., Edsjo, A., Lippolis, G., den Berg, M.S., Bjartell, A., Jenster, G., and Ceder, Y. (2013). miQ-a novel microRNA based diagnostic and prognostic tool for prostate cancer. Int. J. Cancer 132, 2867-2875.
22. Lawrence, M.G., Lai, J., and Clements, J.A. (2010). Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr. Rev. 31, 407-446.
23. Lee, D.Y., Deng, Z., Wang, C.H., and Yang, B.B. (2007). MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl. Acad. Sci. USA 104, 20350-20355.
24. Lichner, Z., Fendler, A., Saleh, C., Nasser, A.N., Boles, D., Al-Haddad, S., Kupchak, P., Dharsee, M., Nuin, P.S., Evans, K.R., et al. (2013). MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin. Chem. 59, 1595-1603.
25. Martens-Uzunova, E.S., Jalava, S.E., Dits, N.F., van Leenders, G.J., Moller, S., Trapman, J., Bangma, C.H., Litman, T., Visakorpi, T., and Jenster, G. (2012). Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 31, 978-991.
26. Mavridis, K. and Scorilas, A. (2010). Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol. 6, 269-285.
27. Mavridis, K., Stravodimos, K., and Scorilas, A. (2013). Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin. Chem. 59, 261-269.
28. Mavridis, K., Avgeris, M., and Scorilas, A. (2014). Targeting kallikrein-related peptidases in prostate cancer. Exp. Opin. Ther. Targets 18, 365-383.
29. Mohler, J., Bahnson, R.R., Boston, B., Busby, J.E., D'Amico, A., Eastham, J.A., Enke, C.A., George, D., Horwitz, E.M., Huben, R.P., et al. (2010). NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl. Compr. Canc. Netw. 8, 162-200.
30. Nagalingam, R.S., Sundaresan, N.R., Gupta, M.P., Geenen, D.L., Solaro, R.J., and Gupta, M. (2013). A cardiac-enriched micro- RNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J. Biol. Chem. 288, 11216-11232.
31. Pasic, M.D., Olkhov, E., Bapat, B., and Yousef, G.M. (2012). Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there. Biol. Chem. 393, 319-330.
32. Porkka, K.P., Pfeiffer, M.J., Waltering, K.K., Vessella, R.L., Tammela, T.L., and Visakorpi, T. (2007). MicroRNA expression profiling in prostate cancer. Cancer Res. 67, 6130-6135.
33. Schaefer, A., Jung, M., Mollenkopf, H.J., Wagner, I., Stephan, C., Jentzmik, F., Miller, K., Lein, M., Kristiansen, G., and Jung, K. (2010a). Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 126, 1166-1176.
34. Schaefer, A., Stephan, C., Busch, J., Yousef, G.M., and Jung, K. (2010b). Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat. Rev. Urol. 7, 286-297.
35. Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009). Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320-1328.
36. Skrzypek, K., Tertil, M., Golda, S., Ciesla, M., Weglarczyk, K., Collet, G., Guichard, A., Kozakowska, M., Boczkowski, J., Was, H., et al. (2013). Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vascularization, and metastasis. Antioxid. Redox Signal. 19, 644-660.
37. Wach, S., Nolte, E., Szczyrba, J., Stohr, R., Hartmann, A., Orntoft, T., Dyrskjot, L., Eltze, E., Wieland, W., Keck, B., et al. (2012). Micro-RNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int. J. Cancer 130, 611-621.